128 related articles for article (PubMed ID: 18314629)
1. Artificial intelligence and bladder cancer arrays.
Wild PJ; Catto JW; Abbod MF; Linkens DA; Herr A; Pilarsky C; Wissmann C; Stoehr R; Denzinger S; Knuechel R; Hamdy FC; Hartmann A
Verh Dtsch Ges Pathol; 2007; 91():308-19. PubMed ID: 18314629
[TBL] [Abstract][Full Text] [Related]
2. Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks.
Catto JW; Linkens DA; Abbod MF; Chen M; Burton JL; Feeley KM; Hamdy FC
Clin Cancer Res; 2003 Sep; 9(11):4172-7. PubMed ID: 14519642
[TBL] [Abstract][Full Text] [Related]
3. Neuro-fuzzy modeling: an accurate and interpretable method for predicting bladder cancer progression.
Catto JW; Abbod MF; Linkens DA; Hamdy FC
J Urol; 2006 Feb; 175(2):474-9. PubMed ID: 16406976
[TBL] [Abstract][Full Text] [Related]
4. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.
Sanchez-Carbayo M; Socci ND; Lozano J; Saint F; Cordon-Cardo C
J Clin Oncol; 2006 Feb; 24(5):778-89. PubMed ID: 16432078
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder.
Wild PJ; Herr A; Wissmann C; Stoehr R; Rosenthal A; Zaak D; Simon R; Knuechel R; Pilarsky C; Hartmann A
Clin Cancer Res; 2005 Jun; 11(12):4415-29. PubMed ID: 15958626
[TBL] [Abstract][Full Text] [Related]
6. A molecular signature in superficial bladder carcinoma predicts clinical outcome.
Dyrskjøt L; Zieger K; Kruhøffer M; Thykjaer T; Jensen JL; Primdahl H; Aziz N; Marcussen N; Møller K; Orntoft TF
Clin Cancer Res; 2005 Jun; 11(11):4029-36. PubMed ID: 15930337
[TBL] [Abstract][Full Text] [Related]
7. The loss of 8p23.3 is a novel marker for predicting progression and recurrence of bladder tumors without muscle invasion.
Eguchi S; Yamamoto Y; Sakano S; Chochi Y; Nakao M; Kawauchi S; Furuya T; Oga A; Matsuyama H; Sasaki K
Cancer Genet Cytogenet; 2010 Jul; 200(1):16-22. PubMed ID: 20513529
[TBL] [Abstract][Full Text] [Related]
8. Bladder cancer outcome and subtype classification by gene expression.
Blaveri E; Simko JP; Korkola JE; Brewer JL; Baehner F; Mehta K; Devries S; Koppie T; Pejavar S; Carroll P; Waldman FM
Clin Cancer Res; 2005 Jun; 11(11):4044-55. PubMed ID: 15930339
[TBL] [Abstract][Full Text] [Related]
9. Promoter hypermethylation identifies progression risk in bladder cancer.
Yates DR; Rehman I; Abbod MF; Meuth M; Cross SS; Linkens DA; Hamdy FC; Catto JW
Clin Cancer Res; 2007 Apr; 13(7):2046-53. PubMed ID: 17404085
[TBL] [Abstract][Full Text] [Related]
10. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study.
Dyrskjøt L; Zieger K; Real FX; Malats N; Carrato A; Hurst C; Kotwal S; Knowles M; Malmström PU; de la Torre M; Wester K; Allory Y; Vordos D; Caillault A; Radvanyi F; Hein AM; Jensen JL; Jensen KM; Marcussen N; Orntoft TF
Clin Cancer Res; 2007 Jun; 13(12):3545-51. PubMed ID: 17575217
[TBL] [Abstract][Full Text] [Related]
11. Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C
Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
[TBL] [Abstract][Full Text] [Related]
12. Identifying distinct classes of bladder carcinoma using microarrays.
Dyrskjøt L; Thykjaer T; Kruhøffer M; Jensen JL; Marcussen N; Hamilton-Dutoit S; Wolf H; Orntoft TF
Nat Genet; 2003 Jan; 33(1):90-6. PubMed ID: 12469123
[TBL] [Abstract][Full Text] [Related]
13. The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression.
Catto JW; Abbod MF; Wild PJ; Linkens DA; Pilarsky C; Rehman I; Rosario DJ; Denzinger S; Burger M; Stoehr R; Knuechel R; Hartmann A; Hamdy FC
Eur Urol; 2010 Mar; 57(3):398-406. PubMed ID: 19913990
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
15. Risk of concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: retrospective analysis of 173 Japanese cases.
Hara T; Takahashi M; Gondo T; Nagao K; Ohmi C; Sakano S; Naito K; Matsuyama H
Int J Urol; 2009 Mar; 16(3):293-8. PubMed ID: 19207607
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer.
Jarmalaite S; Jankevicius F; Kurgonaite K; Suziedelis K; Mutanen P; Husgafvel-Pursiainen K
Oncology; 2008; 75(3-4):145-51. PubMed ID: 18824877
[TBL] [Abstract][Full Text] [Related]
17. Molecular alterations associated with bladder cancer progression.
Sánchez-Carbayo M; Cordon-Cardó C
Semin Oncol; 2007 Apr; 34(2):75-84. PubMed ID: 17382791
[TBL] [Abstract][Full Text] [Related]
18. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer.
Cho KS; Seo HK; Joung JY; Park WS; Ro JY; Han KS; Chung J; Lee KH
J Urol; 2009 Dec; 182(6):2625-30. PubMed ID: 19836779
[TBL] [Abstract][Full Text] [Related]
19. Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors.
Palou J; Rodríguez-Rubio F; Millán F; Algaba F; Rodríguez-Faba O; Huguet J; Villavicencio H
Urology; 2009 Jun; 73(6):1313-7. PubMed ID: 19362341
[TBL] [Abstract][Full Text] [Related]
20. Prognostic markers in muscle invasive bladder cancer.
Tiguert R; Lessard A; So A; Fradet Y
World J Urol; 2002 Aug; 20(3):190-5. PubMed ID: 12196903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
